Warfarin

[EngMac]

Some people who have INR challenges may wish to read this.

medscape.com/viewarticle/84...

[Hidden]

Hi I have tried to read the article but I have to register i am not too sure about having to register and log on can you tell me a little more about it please

[Rellim296 in reply to Hidden]

Ditto

[Froggy]

Hi - tried to look from your link but was asked for a password. It looks like you have given your own personal link as it shows a user name then requests password?

[EngMac]

Yes, this site needs you to set up a user name and password to access its contents like HealthUnlocked. If you do this, you will not receive junk mail. Also you can have AF topics sent to your email should you choose. Doctors use this site so it could be somewhat legit.

Here is the first three paragraphs of the article. I posted it in case some people have issues with Warfarin and maybe this is something to ask about.

BOSTON, MA — Individuals with a genetic-based sensitivity to warfarin have a significantly increased risk of bleeding within the first 90 days of treatment compared with individuals who respond normally to the anticoagulant, a new analysis of the ENGAGE AF-TIMI 48 study has shown[1].

In addition, the individuals classified as sensitive or highly sensitive to warfarin—on the basis of genetic variants of CYP2C9 and VKORC1—derived a greater early safety benefit from edoxaban (Savaysa, Daiichi-Sankyo), the novel factor Xa inhibitor tested in ENGAGE AF-TIMI 48.

"If you look among patients who were treated with warfarin, what we observed was that those who were sensitive or highly sensitive responders to warfarin based on their genotype spend more time overanticoagulated, defined as an INR greater than 3.0, and they also have higher rates of bleeding in the first 90 days," lead investigator Dr Jessica Mega (Brigham and Women's Hospital, Boston, MA) told heartwire from Medscape. "So there was a pharmacologic effect as well as a clinical-outcomes effect."